Sex hormone replacement in ovarian failure - new treatment concepts.

[1]  D. Dunger,et al.  Effect of Oxandrolone and Timing of Oral Ethinylestradiol Initiation on Pubertal Progression, Height Velocity and Bone Maturation in the UK Turner Study , 2014, Hormone Research in Paediatrics.

[2]  C. McEniery,et al.  A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: Study protocol and review of the literature , 2013, Menopause international.

[3]  R. Ouellet-Hellstrom,et al.  Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. , 2013, Contraception.

[4]  C. Kelnar,et al.  Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. , 2012, Human reproduction.

[5]  D. Cimino,et al.  Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells , 2011, Breast Cancer Research and Treatment.

[6]  C. Kelnar,et al.  Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover , 2010, Clinical endocrinology.

[7]  K. Schenck-Gustafsson,et al.  EMAS position statement: Managing women with premature ovarian failure. , 2010, Maturitas.

[8]  R. Rizzoli,et al.  Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. , 2010, Bone.

[9]  Barbara Sternfeld,et al.  Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? , 2009, Journal of the American College of Cardiology.

[10]  L. Nelson.  Clinical practice. Primary ovarian insufficiency. , 2009, The New England journal of medicine.

[11]  D. Webb,et al.  Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure , 2009, Hypertension.

[12]  W. Rocca,et al.  Increased Mortality for Neurological and Mental Diseases following Early Bilateral Oophorectomy , 2009, Neuroepidemiology.

[13]  E. D. de Vries,et al.  Cardiovascular toxicity caused by cancer treatment: strategies for early detection. , 2009, The Lancet. Oncology.

[14]  N. Panay,et al.  Management of premature ovarian failure. , 2009, Best practice & research. Clinical obstetrics & gynaecology.

[15]  Walter A. Rocca,et al.  Increased cardiovascular mortality after early bilateral oophorectomy , 2009, Menopause.

[16]  J. Cline,et al.  Transcriptional profiles of progestogen effects in the postmenopausal breast , 2009, Breast Cancer Research and Treatment.

[17]  G. Lowe,et al.  Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[18]  N. Panay,et al.  Spontaneous premature ovarian failure: Management challenges , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  P. Hagerman,et al.  A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. , 2008, The Journal of molecular diagnostics : JMD.

[20]  G. Ertl,et al.  Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. , 2008, Cardiovascular research.

[21]  R. Lobo.  Surgical menopause and cardiovascular risks , 2007, Menopause.

[22]  J. Manson,et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. , 2007, JAMA.

[23]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[24]  R. Milne,et al.  Recombinant growth hormone for children and adolescents with Turner syndrome. , 2007, The Cochrane database of systematic reviews.

[25]  Mariza de Andrade,et al.  Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. , 2006, The Lancet. Oncology.

[26]  N. Keiding,et al.  The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. , 2006, Maturitas.

[27]  C. E. Wood,et al.  Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys , 2006, Breast Cancer Research and Treatment.

[28]  C. Farquhar,et al.  The association of hysterectomy and menopause: a prospective cohort study , 2005, BJOG : an international journal of obstetrics and gynaecology.

[29]  A. Verbeek,et al.  Age at Menopause, Cause-Specific Mortality and Total Life Expectancy , 2005, Epidemiology.

[30]  L. Nelson,et al.  An update: spontaneous premature ovarian failure is not an early menopause. , 2005, Fertility and sterility.

[31]  L. Mosekilde,et al.  Effect of growth hormone and 17β‐oestradiol treatment on metabolism and body composition in girls with Turner syndrome , 2005, Clinical endocrinology.

[32]  D. Stephure.  Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. , 2005, The Journal of clinical endocrinology and metabolism.

[33]  H. Critchley,et al.  Impact of cancer treatment on uterine function. , 2005, Journal of the National Cancer Institute. Monographs.

[34]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[35]  T. Chataigneau,et al.  Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats , 2004, Menopause.

[36]  C. Christiansen,et al.  Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. , 2004, Bone.

[37]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[38]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[39]  P. Vestergaard,et al.  Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey , 2003, Clinical endocrinology.

[40]  T. Stijnen,et al.  Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. , 2003, The Journal of clinical endocrinology and metabolism.

[41]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[42]  L. Nelson,et al.  Meeting the Needs of Young Women With Secondary Amenorrhea and Spontaneous Premature Ovarian Failure , 2002, Obstetrics and gynecology.

[43]  A. Hollman,et al.  Poor uterine development in Turner syndrome with oral oestrogen therapy , 2002, Clinical endocrinology.

[44]  C. Kelnar,et al.  Choice of hormone replacement therapy in young women with ovarian failure , 2001, Clinical endocrinology.

[45]  A. Pasquino,et al.  Recommendations for the diagnosis and management of Turner syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[46]  J. Hsia,et al.  Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS) , 2001, Circulation.

[47]  G. Conway.  Oestrogen replacement in young women with Turner's syndrome* , 2001, Clinical endocrinology.

[48]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[49]  van Kasteren Ym.  Premature ovarian failure , 2000 .

[50]  O. Joakimsen,et al.  Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromsø Study. , 2000, Journal of clinical epidemiology.

[51]  G. Conway,et al.  The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[52]  C. Kelnar,et al.  Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement , 1999, British journal of obstetrics and gynaecology.

[53]  L. Dalprà,et al.  The idiopathic forms of premature menopause and early menopause show the same genetic pattern. , 1999, Human reproduction.

[54]  E. Dudley,et al.  Weight gain and the menopause: a 5-year prospective study. , 1999, Climacteric : the journal of the International Menopause Society.

[55]  J. Schoemaker,et al.  Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. , 1999, Human reproduction update.

[56]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[57]  P. Sundström.  Establishment of a successful pregnancy following in-vitro fertilization with an endometrial thickness of no more than 4 mm. , 1998, Human reproduction.

[58]  G. Cooper,et al.  Age at natural menopause and mortality. , 1998, Annals of epidemiology.

[59]  L. Nelson,et al.  Bone Loss in Young Women With Karyotypically Normal Spontaneous Premature Ovarian Failure , 1998, Obstetrics and gynecology.

[60]  C. Simón,et al.  Endometrial thickness and serum oestradiol concentrations as predictors of outcome in oocyte donation. , 1997, Human reproduction.

[61]  M. Adams,et al.  Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[62]  W. Fraser,et al.  Exaggerated effects of progestogen on uterine artery pulsatility index in Turner's syndrome patients receiving hormone replacement therapy. , 1995, Fertility and sterility.

[63]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[64]  J. Higginson,et al.  Abdominal irradiation in childhood; the potential for pregnancy , 1992, British journal of obstetrics and gynaecology.

[65]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[66]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[67]  M. Hall,et al.  Bone mineral loss in young women with amenorrhoea. , 1990 .

[68]  C. H. Buckley,et al.  Experience with a ‘physiological’ steroid replacement regimen for the establishment of a receptive endometrium in women with premature ovarian failure , 1990, British journal of obstetrics and gynaecology.

[69]  Rw Rebar,et al.  Clinical features of young women with hypergonadotropic amenorrhea , 1990, Fertility and sterility.

[70]  K. Matthews,et al.  Menopause and Risk Factors for Coronary Heart Disease , 1989 .

[71]  A. Hofman,et al.  Increased risk of atherosclerosis in women after the menopause. , 1989, BMJ.

[72]  J M Tanner,et al.  Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length, limb length, and muscle width in growth hormone-deficient children. , 1976, The Journal of pediatrics.

[73]  W. Kannel,et al.  Menopause and Risk of Cardiovascular Disease: The Framingham Study , 1976 .